Cargando…

Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy

Previous literature regarding coronavirus disease 2019 outlined a presence of organ dysfunction including acute respiratory distress syndrome and acute kidney injury that are linked to mortality. Several patients require extracorporeal therapy. This review aims to gather available published resource...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaijamorn, Weerachai, Rungkitwattanakul, Dhakrit, Nuchtavorn, Nantana, Charoensareerat, Taniya, Pattharachayakul, Sutthiporn, Sirikun, Wiriyaporn, Srisawat, Nattachai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531758/
https://www.ncbi.nlm.nih.gov/pubmed/33063039
http://dx.doi.org/10.1097/CCE.0000000000000242
_version_ 1783589792814989312
author Chaijamorn, Weerachai
Rungkitwattanakul, Dhakrit
Nuchtavorn, Nantana
Charoensareerat, Taniya
Pattharachayakul, Sutthiporn
Sirikun, Wiriyaporn
Srisawat, Nattachai
author_facet Chaijamorn, Weerachai
Rungkitwattanakul, Dhakrit
Nuchtavorn, Nantana
Charoensareerat, Taniya
Pattharachayakul, Sutthiporn
Sirikun, Wiriyaporn
Srisawat, Nattachai
author_sort Chaijamorn, Weerachai
collection PubMed
description Previous literature regarding coronavirus disease 2019 outlined a presence of organ dysfunction including acute respiratory distress syndrome and acute kidney injury that are linked to mortality. Several patients require extracorporeal therapy. This review aims to gather available published resources including physicochemical and pharmacokinetic properties and suggests antiviral drug dosing adaptation for coronavirus disease 2019–infected critically ill patients receiving extracorporeal therapy. A literature search was performed using PubMed, clinical trial registries, and bibliographic review of textbooks and review articles. Unfortunately, no standard of pharmacologic management and recommendations of drug dosing for coronavirus disease 2019 infection for critically ill patients receiving extracorporeal therapy exist due to the limited data on pharmacokinetic and clinical studies. All available extracted data were analyzed to suggest the appropriate drug dosing adjustment. Antiviral drug dosing adjustments for critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy are presented in this review. Considering pathophysiologic changes, drug properties, and extracorporeal modalities, applying our suggestions is recommended.
format Online
Article
Text
id pubmed-7531758
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75317582020-10-14 Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy Chaijamorn, Weerachai Rungkitwattanakul, Dhakrit Nuchtavorn, Nantana Charoensareerat, Taniya Pattharachayakul, Sutthiporn Sirikun, Wiriyaporn Srisawat, Nattachai Crit Care Explor Commentary Previous literature regarding coronavirus disease 2019 outlined a presence of organ dysfunction including acute respiratory distress syndrome and acute kidney injury that are linked to mortality. Several patients require extracorporeal therapy. This review aims to gather available published resources including physicochemical and pharmacokinetic properties and suggests antiviral drug dosing adaptation for coronavirus disease 2019–infected critically ill patients receiving extracorporeal therapy. A literature search was performed using PubMed, clinical trial registries, and bibliographic review of textbooks and review articles. Unfortunately, no standard of pharmacologic management and recommendations of drug dosing for coronavirus disease 2019 infection for critically ill patients receiving extracorporeal therapy exist due to the limited data on pharmacokinetic and clinical studies. All available extracted data were analyzed to suggest the appropriate drug dosing adjustment. Antiviral drug dosing adjustments for critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy are presented in this review. Considering pathophysiologic changes, drug properties, and extracorporeal modalities, applying our suggestions is recommended. Lippincott Williams & Wilkins 2020-10-01 /pmc/articles/PMC7531758/ /pubmed/33063039 http://dx.doi.org/10.1097/CCE.0000000000000242 Text en Copyright © 2020 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Commentary
Chaijamorn, Weerachai
Rungkitwattanakul, Dhakrit
Nuchtavorn, Nantana
Charoensareerat, Taniya
Pattharachayakul, Sutthiporn
Sirikun, Wiriyaporn
Srisawat, Nattachai
Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
title Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
title_full Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
title_fullStr Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
title_full_unstemmed Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
title_short Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy
title_sort antiviral dosing modification for coronavirus disease 2019–infected patients receiving extracorporeal therapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531758/
https://www.ncbi.nlm.nih.gov/pubmed/33063039
http://dx.doi.org/10.1097/CCE.0000000000000242
work_keys_str_mv AT chaijamornweerachai antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy
AT rungkitwattanakuldhakrit antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy
AT nuchtavornnantana antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy
AT charoensareerattaniya antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy
AT pattharachayakulsutthiporn antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy
AT sirikunwiriyaporn antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy
AT srisawatnattachai antiviraldosingmodificationforcoronavirusdisease2019infectedpatientsreceivingextracorporealtherapy